Pliant Therapeutics (PLRX) Earnings Analysis
Pliant Therapeutics (PLRX) next reports earnings on 2026-08-06, consensus EPS -0.33 USD. Last quarter (2026-05-11) it beat with EPS -0.32 USD vs -0.36 USD est (+11.1%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E -0.60.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PLRX next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.33 USD |
| Revenue estimate | n/a |
PLRX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.32 USD | -0.36 USD | +11.1% | Beat |
| 2026-03-11 | -0.35 USD | -0.42 USD | +16.7% | Beat |
| 2025-11-06 | -0.43 USD | -0.53 USD | +18.9% | Beat |
| 2025-08-07 | -0.71 USD | -0.62 USD | -14.5% | Miss |
| 2025-05-08 | -0.92 USD | -0.78 USD | -17.9% | Miss |
| 2025-03-03 | -0.82 USD | -0.99 USD | +17.2% | Beat |
| 2024-11-07 | -0.95 USD | -0.99 USD | +4% | Beat |
Beat rate: 5/7 (71%) over reported quarters with consensus data.
PLRX valuation and analyst view
| Trailing P/E | -0.60 |
|---|---|
| Trailing EPS | -1.8319 USD |
| Price / book | 0.41 |
| Dividend yield | 0.00% |
| Market cap | 0.07B |
| Analyst consensus | Buy (8 buy / 7 hold / 1 sell) |
| Avg price target | 3 USD |
Related research pages
Frequently asked questions
When is Pliant Therapeutics (PLRX)'s next earnings date?
Pliant Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.33 USD.
Did PLRX beat earnings last quarter?
In its 2026-05-11 report, PLRX posted EPS of -0.32 USD versus a -0.36 USD estimate — a beat of 11.1%.
What is PLRX's earnings track record?
Over the last 7 reported quarters with consensus data, PLRX beat estimates 5 times (71%).
What is PLRX's current P/E ratio and EPS?
PLRX trades at a trailing P/E of -0.60 on trailing EPS of -1.8319037021013724 USD.
What do analysts rate PLRX?
Analyst consensus is "Buy" across 16 ratings (0 strong buy, 8 buy, 7 hold, 1 sell, 0 strong sell). Average 12-month price target: 3 USD.